Related Experiment Videos
Extrapancreatic insulin effect of glibenclamide
H Mulder1, W Schopman, A J van der Lely
1Department of Internal Medicine, Eudokia Hospital, Rotterdam, Netherlands.
European Journal of Clinical Pharmacology
|January 11, 1991
Summary
Glibenclamide prolonged insulin levels in patients with non-insulin-dependent diabetes mellitus. This drug inhibits insulin degradation, contributing to its blood glucose-lowering effect.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Disorders
Background:
- Non-insulin-dependent diabetes mellitus (NIDDM) management often involves improving insulin secretion and action.
- Glibenclamide is a sulfonylurea drug used to treat NIDDM.
Purpose of the Study:
- To investigate the effect of glibenclamide on serum insulin and C-peptide levels in patients with NIDDM.
- To determine the mechanism by which glibenclamide influences insulin pharmacokinetics and glucose control.
Main Methods:
- Eight patients with uncomplicated NIDDM participated in the study.
- Serum insulin, C-peptide, and blood glucose levels were measured before and after oral glibenclamide (0.1 mg/kg) plus a test meal, or a test meal alone.
- Measurements were taken over a 5-hour period.
Main Results:
- Glibenclamide administration resulted in a more prolonged rise in serum insulin levels compared to the test meal alone.
- The initial increase in serum insulin and C-peptide levels was similar in both treatment groups.
- Serum C-peptide levels showed a similar rise during the entire 5-hour study period.
Conclusions:
- Glibenclamide prolongs serum insulin levels by inhibiting insulin degradation in hepatic vascular endothelial cells.
- This inhibition of insulin degradation contributes to the blood glucose-lowering efficacy of glibenclamide in NIDDM patients.